VNDA

Joakim Wijkstrom

Known title: SVP, Chief Marketing OfficerCIK: 0001785888

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

September 26, 2026

Oppenheimer Launches Coverage on Vanda Pharmaceuticals. Oppenheimer has begun covering Vanda Pharmaceuticals, issuing an outperform rating and a $10 price target. The target sits near the middle of the analyst range and below the 52‑week high, suggesting a cautious upside view. The stock is trading above its $5.21 support level with an RSI of 41.6, indicating room for movement.

this person other insiders at VNDA

Transaction History

VNDA▼ Sell$255K
VNDA▲ Buy$0
VNDA▼ Sell$74K
VNDA▲ Buy$0
VNDA▼ Sell$39K
VNDA▼ Sell$33K
VNDA▲ Buy$0
VNDA▼ Sell$22K
VNDA▼ Sell$26K
VNDA▼ Sell$48K
VNDA▲ Buy$0
VNDA▼ Sell$37K
VNDA▼ Sell$78K
VNDA▲ Buy$0

We use analytics to understand how market-wall is used. No personal data is sold.